CancerPsychosocial FunctioningTreatment Side EffectsCachexia
Study summary
Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint inhibitors
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Aged 18 years or older
* Having undergone a CT scan (at the L3 level) prior to treatment
* No severe mental disorder and able to communicate effectively
* Provided written informed consent
Exclusion Criteria:
* Did not provide written informed consent
* Patients deemed unsuitable by the physician
Primary outcome measure(s)
Body composition evaluation — Patient recruitment is planned to occur over a 6-month period. Each participant will be followed for a maximum duration of 6 months from the initiation of immunotherapy. Body Composition Parameters Description: Muscle area, muscle index, muscle density, lean body mass, and combined indices derived from routine abdominal imaging at the L3 vertebral level.
Unit of measure: cm², cm²/m², Hounsfield units (HU), kilograms. Tool: Routine clinical imaging analysis.
Trial sites (1)
Facility
City
Region
Status
Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.